SCHEMBL19782802

SCHEMBL19782802

COc1ccc(-c2cc(-c3ccc(O)c(OC)c3)[nH]c(=O)n2)c(OC)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCL12 P48061 1/20 0.64
CDC7 O00311 3/20 0.55
KDM4E B2RXH2 5/20 0.52
MEN1 O00255 4/20 0.48
KMT2A Q03164 4/20 0.48
MAPT P10636 3/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
FYN P06241 1/20 0.47
RIPK1 Q13546 1/20 0.46
CSNK2A2 P19784 3/20 0.45
CSNK2B P67870 3/20 0.45
CSNK2A1 P68400 3/20 0.45
PIM1 P11309 1/20 0.45
CLK1 P49759 1/20 0.45
GSK3B P49841 1/20 0.45
CSNK2A3 Q8NEV1 1/20 0.45
LMNA P02545 2/20 0.44
HPGD P15428 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19782680 0.88 CXCL12 (0.72) CXCL12CDC7KDM4EMEN1KMT2A
SCHEMBL19782361 0.86 CXCL12 (0.66) CXCL12CDC7KDM4EMEN1KMT2A
SCHEMBL385492 0.82 CDC7 (0.64) CXCL12CDC7KDM4EMEN1KMT2A
SCHEMBL19782360 0.82 CXCL12 (0.74) CXCL12CDC7KDM4EFYNRIPK1
SCHEMBL19782359 0.81 CXCL12 (0.72) CXCL12CDC7KDM4ERIPK1CSNK2A2
SCHEMBL19782920 0.81 CXCL12 (0.72) CXCL12CDC7KDM4EFYNRIPK1
SCHEMBL19782804 0.81 CXCL12 (0.65) CXCL12CDC7KDM4EMEN1KMT2A
SCHEMBL19782801 0.81 CXCL12 (0.69) CXCL12CDC7KDM4EMEN1KMT2A
SCHEMBL19782800 0.80 CXCL12 (0.71) CXCL12CDC7KDM4EFYNRIPK1
SCHEMBL19782832 0.80 CXCL12 (0.71) CXCL12CDC7KDM4EFYNRIPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11046657-B2 Pyrimidinone derivatives and uses thereof to neutralize the biological activity of chemokines CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2021-06-29 US disclosed
US-11046657-B2 Pyrimidinone derivatives and uses thereof to neutralize the biological activity of chemokines CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2021-06-29 US disclosed
US-20200181093-A1 Pyrimidinone Derivatives and Uses Thereof to Neutralize the Biological Activity of Chemokines CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) 2020-06-11 US disclosed
US-20200181093-A1 Pyrimidinone Derivatives and Uses Thereof to Neutralize the Biological Activity of Chemokines CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) 2020-06-11 US disclosed
EP-3484864-A1 PYRIMIDINONE DERIVATIVES AND USES THEREOF TO NEUTRALIZE THE BIOLOGICAL ACTIVITY OF CHEMOKINES Centre National de la Recherche Scientifique - CNRS (FR) 2019-05-22 EP disclosed
WO-2018011376-A1 PYRIMIDINONE DERIVATIVES AND USES THEREOF TO NEUTRALIZE THE BIOLOGICAL ACTIVITY OF CHEMOKINES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS - (FR) 2018-01-18 WO disclosed
WO-2018011376-A1 PYRIMIDINONE DERIVATIVES AND USES THEREOF TO NEUTRALIZE THE BIOLOGICAL ACTIVITY OF CHEMOKINES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS - (FR) 2018-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200181093-A1 Pyrimidinone Derivatives and Uses Thereof to Neutralize the Biological Activity of Chemokines CCL5, CXCR3, CXCL10 CXCL12 18/4885CDC7 2413/4885KDM4E 4286/4885
US-11046657-B2 Pyrimidinone derivatives and uses thereof to neutralize the biological activity of chemokines CCL5, CXCR3, CXCL10 CXCL12 18/4885CDC7 2413/4885KDM4E 4286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.